September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Matt Regan, a seasoned leader in the healthcare and life sciences industry, has recently joined the Board of Directors at Portal Instruments. This strategic move brings valuable expertise to Portal, a company focused on revolutionizing drug delivery through its innovative needle-free injection technology.
Regan's addition to the board underscores Portal Instruments' commitment to innovation and growth. His pharmaceutical insights and leadership will play a crucial role in shaping the company's future as it continues to advance its technology.
March 2021 - With the COVID-19 vaccine becoming more readily available, there is the outstanding question of how many people will get vaccinated and will it be enough to help society as a whole achieve herd immunity.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Portal Instruments today announced that it will further expand its partnership with Gerresheimer, an innovative system and solution provider and a global partner for the pharma, biotech and cosmetic industries, to commercialize the Prime NEXUS™ reusable, connected autoinjector platform.
Please fill out the details below and we will get back to you shortly.